Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
Masahiro Seike(Nippon Medical School Hospital), T. Nukiwa(Tohoku University), Toshiyuki Harada(Hokkaido hospital), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Kei Takamura(Obihiro Kosei General Hospital), Yasuko Fujita, A. Inoue, Satoshi Ikeda, Shunichi Sugawara(Sendai Kousei Hospital), Kazuhisa Takahashi(Kansai Medical University), Satoshi Morita(Kyoto University), Kunihiko Kobayashi(Saitama International Medical Center), Kana Watanabe(Miyagi Prefectural Hospital Organization), Koichi Minato
Cited by 10
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695